Printer Friendly

T CELL SCIENCES REPORTS 1992 FINANCIAL RESULTS; FIGURES REFLECT CHANGE TO CALENDAR YEAR END

 CAMBRIDGE, Mass., March 8 /PRNewswire/ -- T Cell Sciences, Inc., (NASDAQ: TCEL) today announced financial results for the two months ended Dec. 31, 1992 and the eight month fiscal period ended Dec. 31, 1992. In October 1992, the company changed its fiscal year from an April 30 year end to Dec. 31 year end. Therefore, the results reported today relate to the transition period May 1, 1992 to Dec. 31, 1992, as well as to the two months ended Dec. 31, 1992. For the two month period ended Dec. 31, 1992 revenues totaled $1,352,000 and expenses were $2,994,000. The net loss for the period was $1,320,000 (10 cents per share). In the comparable period last year, there was a net loss of $1,467,000 (11 cents per share), on revenues of $733,000 and expenses of $2,543,000.
 For the eight months ended Dec. 31, 1992, the company reported revenues of $6,586,000 and expenses of $11,287,000. The net loss for the period was $3,633,000 (27 cents per share). In the same period ended Dec. 31, 1991, there were revenues of $4,186,000, and expenses of $9,706,000. The net loss for the 1991 period was $4,221,000 (32 cents per share). The company's cash and investment position as of Dec. 31, 1992 was $17,546,000.
 "The 14 percent reduction in the net loss for the period ended Dec. 31, 1992 reflects the inclusion of product development revenues from AB Astra, our partner in developing T cell antigen receptor therapeutics for autoimmune diseases and T cell cancers," said Alan W. Tuck, president and chief executive officer of T Cell Sciences, Inc. "Based on an agreement signed in January 1992, Astra may provide up to $15 million of initial research funding and additional funding of up to $17 million over several years." Tuck added, "1992 was a successful year for T Cell Sciences. The Astra agreement was signed, the management team was strengthened, the company filed for marketing approval for its TRAx(tm) CD4 product and clinical trials were initiated for its first therapeutic, sCR1, for the treatment of burn patients at risk of developing adult respiratory distress syndrome."
 Located in Cambridge, Mass., T Cell Sciences, Inc. is utilizing proprietary T cell and soluble receptor technology to develop pharmaceutical products to treat diseases of inflammation, autoimmunity and cancer. T Cell Diagnostics, an 84 percent owned subsidiary of T Cell Sciences, develops, manufactures and markets innovative diagnostic and research products.
 T CELL SCIENCES, INC.
 Comparative Statements of Operations
 Two Months Ended Eight Months Ended
 Dec. 31 Dec. 31
 1992 1991 1992 1991
 Revenues:
 Product $585,000 $434,000 $2,523,000 $2,507,000
 Product
 development 767,000 299,000 4,063,000 1,680,000
 Interest 208,000 268,000 803,000 1,119,000
 Total revenue 1,560,000 1,001,000 7,389,000 5,305,000
 Total operating
 expenses 2,994,000 2,543,000 11,287,000 9,706,000
 Net loss before
 minority
 interest (1,434,000)(1,542,000) (3,898,000) (4,400,000)
 Minority interest
 share of loss 114,000 75,000 265,000 179,000
 Net loss after
 minority
 interest (1,320,000)(1,467,000) (3,633,000) (4,221,000)
 Net loss per
 share (10 cents) (11 cents) (27 cents) (32 cents)
 Weighted average
 common shares
 outstanding 13,418,000 13,216,000 13,390,000 13,027,000
 (Figures reflect change from April 30 to Dec. 31, year end)
 -0- 3/8/93
 /CONTACT: Susan Primrose, manager of corporate development & communications or Jacqueline Arthur, vice president and chief financial officer, 617-621-1400, both of T Cell Sciences, Inc.
 (TCEL)


CO: T Cell Sciences Inc. ST: Massachusetts IN: MTC SU: ERN

DJ -- NE010 -- 4150 03/08/93 15:21 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 8, 1993
Words:645
Previous Article:ANGELES CORP. SUSPENDS SEMIANNUAL DISTRIBUTION ON UNITS
Next Article:MICHAEL P.W. STONE, FORMER SECRETARY OF ARMY, NAMED TO BOARD OF DIRECTORS OF BEI ELECTRONICS, INC.
Topics:


Related Articles
T CELL SCIENCES REPORTS FISCAL YEAR 1992 FINANCIAL RESULTS
SYSTEMIX REPORTS SECOND QUARTER AND SIX MONTH RESULTS
T CELL SCIENCES REPORTS FIRST QUARTER RESULTS
ALPHA 1 BIOMEDICALS, INC. REPORTS THIRD QUARTER CALENDAR YEAR 1992 RESULTS
ONCOGENE SCIENCE, INC. REPORTS FIRST QUARTER RESULTS
ADVANCED TISSUE SCIENCES INC. REPORTS 1992 RESULTS
NEORX REPORTS FIRST QUARTER 1993 RESULTS
T CELL SCIENCES REPORTS FIRST QUARTER RESULTS
T CELL SCIENCES REPORTS SECOND QUARTER RESULTS
T CELL SCIENCES REPORTS THIRD QUARTER RESULTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters